Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in NF2-related tumors
NCT03095248Phase 2Terminated
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- May 2017
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in neurofibromatosis type 2 (NF2), vestibular schwannoma (VS), meningioma, ependymoma, glioma, sponsored by Cincinnati Children's Hospital Medical Center. Started May 2017; status: terminated.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 2 (NF2)vestibular schwannoma (VS)meningiomaependymomaglioma
Beyond the preview
Go deeper on NCT03095248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03095248.